Popular Articles

New UK Developed Anti-Bacterial Drug {Metallo-Porphyrin} Unveiled At Leading European Microbiology Congress
Yesterday"s 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) conference in Helsinki reported a significant addition to the dwindling number of drugs in the fight against the hospital "Superbug", Methicillin Resistant Staphylococcus aureus (MRSA).
generic viagra online
Radiofrequency Ablation Durable After 2 Years, Compares Favorably With Endoscopic Resection For Advanced Disease, Reduces Risk For Cancer Progression
Results from a number of clinical trials were presented during the Digestive Disease Week (DDW) in Chicago this week, revealing new outcomes data related to endoscopic radiofrequency ablation using the HALO ablation system for eradicating a pre-cancerous esophageal condition known as Barrett"s esophagus. Among them, reports included durability outcomes from a randomized sham-controlled trial, safety and efficacy outcomes from a large U.S. registry of 429 patients, a randomized trial comparing ablation to endoscopic resection, and the largest European series to date in patients with high-grade dysplasia and early cancer.
News of the day
Neurons That 'Mirror' The Attention Of Others Discovered By Scientists
Whether a monkey is looking to the left or merely watching another monkey looking that way, the same neurons in his brain are firing, according to researchers at the Duke University Medical Center.
Oncology

Xcelience Reduces Time To Phase I Studies By 17 Weeks Using API Into Capsule Services

Xcelience, a leader in early drug development services, has developed a faster, more cost effective path to Phase I studies using Xcelodose® 600 and 600 S precision powder micro-dosing systems (Xcelodose® is a registered trademark of Capsugel® BVBA). API into Capsule projects are on average completed 45 percent faster than traditional formulation efforts, and in some specific cases we have saved our clients as much as 17 weeks. "Today"s molecule is under pressure," says Derek Hennecke, CEO and President. "We need to work smarter with clients to make the best choices, often with limited material. One of the best decisions we made was to put our money on Xcelodose ®. We were the first CRO in North America to do so, we"ve built up industry leading expertise, and this month we are proud to announce our 100th GMP batch." "Our defined API into Capsule program is a true differentiator, but not the only one," adds V.P. Randall H. Guthrie. "Xcelience combines decades of drug development experience, state-of-the-art equipment, a strong audit history, and sound financial management to deliver solutions that enable our clients to rely on us to accelerate drug development programs and meet critical milestones." Xcelience is also announcing a strategic expansion focused on areas of proven strength: low weight fills and potent compounds for API into capsule, continued expansion and growth of its formulation development team, implementation of UPLC analytical capability, investment in x-ray diffraction for preformulation activities, and blister packaging in support of client"s clinical supply needs. Development of the purpose-built Grace Street expansion continues as planned. Xcelience LLC, is a contract research organization which has been providing formulation development, preformulation, analytical, and clinical trial manufacturing since 1997. The company has a solid reputation for accelerating early development activities to speed potential drugs to clinical trials while applying stage-specific scientific knowledge and experience. Xcelience"s unique corporate structure creates project teams that work intensively with each client, bringing an extension of their own organization into the Xcelience lab. Xcelience LLC


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):